Tetrapeptide Ingredients TRIZ Cases
- Dolastatin Derivatives With Non-Natural Amino Acid Linkers
Orthogonal non-natural amino acids add aldehyde, azide, or hydroxylamine groups to proteins for selective, stable covalent linkage formation.
- Dolaproine-Dolaisoleuine Peptide Analogs for Stable Microtubule Disruption
Structural changes to dolaproine-dolaisoleuine peptides improve metabolic stability while preserving microtubule-disrupting anticancer activity.
- Protein-Drug Conjugate Linkers for Stable, Targeted Drug Release
A dual-linker protein-drug conjugate balances plasma stability with hydrolase-cleavable release while controlling payload ratio to limit aggregation.
- Pyrazolopyrimidine Urea nsp5 Inhibitor for COVID-19 Treatment
Targeting SARS-CoV-2 nsp5 protease with a pyrazolopyrimidine urea compound helps suppress viral replication and reduce COVID-19 severity.
- Tasquinimod Combination Therapy for Relapse-Resistant Multiple Myeloma
Combining tasquinimod with proteasome inhibitors, immunomodulatory imides, and antibodies helps counter myeloma relapse and resistance.
- Aromatic-Cationic Peptide Therapy for TAZ1 Expression in Barth Syndrome
An aromatic-cationic peptide raises TAZ1 expression to stabilize cardiolipin remodeling and reduce Barth syndrome severity.
- MMAE Purification by Back-Titration Crystallization
Reverse dropwise solvent crystallization replaces silica gel chromatography to purify MMAE with higher yield, purity, and scale-up efficiency.
- PKCα-Derived Peptides for NAFLD Fibrosis via FATP2 Suppression
Targeting adipose FATP2 with PKCα-derived peptides reduces liver steatosis, triglycerides, and fibrosis when existing NAFLD treatments fall short.